Date:8/14/2009

debt, net of current portion, related party 1,072,742 2,137,742 Deferred income 11,224,209 11,208,844 Total non current liabilities 12,296,951 13,346,586 Total liabilities 40,129,214 47,031,443 EQUITY: Shareholders' equity of the Company: Common stock, $0.001 par value, 250,000,000 shares authorized, 71,333,586 issued and outstanding, respectively 71,334 71,334 Paid-in-capital 9,385,565 9,234,123 Statutory reserves 13,217,217 9,420,783 Retained earnings 121,298,044 106,325,356 Accumulated other comprehensive income 24,062,054 23,851,062 Total shareholders' equity of the company 168,034,214 148,902,658 Noncontrolling interest 9,578,177 9,006,438 Total equity 177,612,391 157,909,096 Total liabilities and equity $217,741,605 $204,940,539 TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2009 AND 2008 (UNAUDITED) Six months ended June 30, 2009 2008 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $19,315,168 $10,137,582 Adjustments to reconcile net income to cash provided by (used in) operating activities: Provision for doubtful accounts (196,863) 37,715 Depreciation 1,112,849
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Tiens Biotech Group (USA) Reports First Quarter Results
2. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
3. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
4. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
5. Biotech Hot in July Driven by Positive Drug Data and Acquisitions
6. Cardinal Health Completes Biotech Acquisition
7. Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
8. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
9. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
10. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
11. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan